A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
Summary
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: * The study duration will be up to 7-8 months. * The double-blind treatment duration will be up to 6 months. * There will be 5 in-clinic visits and 7 phone calls
Timeline
- Start
- 2022-08-03
- Primary completion
- 2023-12-04
- Completion
- 2023-12-04
Outcome
Met primary endpoint
release “today announced new data from its Phase III PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor activities” annovisbio.com ↗
release “Buntanetap’s activity resulted in statistically significant improvements in all primary and secondary endpoints in the specified populations as well as in cognition.” annovisbio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | buntanetap | Small molecule | 10 mg | Oral |
| Subject | buntanetap | Small molecule | 20 mg | Oral |